title: Glaucoma arrives on managed care's doorstep.
abstract: Popular new prostaglandins, prostamides, and alpha2 agonists have brought about higher utilization, while their expense has produced a new cost driver in managed care organizations. The recent appearance of competitive products within these drug classes has offered patients, health plans, and physicians new treatment options.
authors.affiliation: Health Partners, Philadelphia, USA.
authors.forename: Sharad S
authors.initials: SS
authors.lastname: Mansukani
mesh_terms: D016527:Drug Costs; D004363:Drug Utilization; D005901:Glaucoma / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D008329:Managed Care Programs / Q000191:economics*; D011157:Population Dynamics; D011453:Prostaglandins / Q000627:therapeutic use; D014481:United States
chemical_list: D011453:Prostaglandins